Solu Clinipharm Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-06-2024
- Paid Up Capital ₹ 0.10 M
as on 23-06-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 4.00 M
as on 23-06-2024
- Revenue -24.55%
(FY 2021)
- Profit -52.98%
(FY 2021)
- Ebitda 729.83%
(FY 2021)
- Net Worth 11.74%
(FY 2021)
- Total Assets 44.37%
(FY 2021)
About Solu Clinipharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Sangeeta Iyer and Natrajan Iyer serve as directors at the Company.
- CIN/LLPIN
U74900MH2012PTC226456
- Company No.
226456
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2012
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Solu Clinipharm Private Limited offer?
Solu Clinipharm Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Anti Infective Drugs & Medicines, HIV Drugs, Common Disease Medicines, Anti Smoking Drugs.
Who are the key members and board of directors at Solu Clinipharm?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Natrajan Iyer  | Director | 25-Jan-2012 | Current |
| Sangeeta Iyer | Director | 25-Jan-2012 | Current |
Financial Performance of Solu Clinipharm.
Solu Clinipharm Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 24.55% decrease. The company also saw a substantial fall in profitability, with a 52.98% decrease in profit. The company's net worth Soared by an impressive increase of 11.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Solu Clinipharm?
In 2021, Solu Clinipharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Jan 2017 | ₹4.00 M | Open |
How Many Employees Work at Solu Clinipharm?
Unlock and access historical data on people associated with Solu Clinipharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Solu Clinipharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Solu Clinipharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
